CRSP

#1107
CRISPR Therapeutics AG - Common Shares
56.1 8 USD
-0.35%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
56.18
56.18
년간 변동
35.48
78.48
일일 변동
-0.35%
월간 변동
+9.47%
6달 변화
+7.42%
년간 변동율
+52.25%
이전 종가
56.3 8
Open
56.1 8
저가
56.1 8
High
56.1 8
양
132
전체 차트 열기 Full chart

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 5.42 B
  • Employee 393
  • Founded 2013
  • CEO Samarth Kulkarni
  • Website www.crisprtx.com
  • Headquarter Switzerland
  • FIGI UNKNOWN
  • Industry 생명공학
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
-8.11
주가매출액비율
1 343.5

CRISPR Therapeutics AG - Common Shares

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.

뉴스